By Helgi Library - November 24, 2020
Saneca Pharmaceuticals stock traded at EUR 20.3 per share at the end 2019 translating into a market capitalization of USD 22.8 mil. ...
By Helgi Library - November 24, 2020
Saneca Pharmaceuticals stock traded at EUR 20.3 per share at the end 2019 translating into a market capitalization of USD 22.8 mil. ...
By Helgi Library - November 25, 2020
Saneca Pharmaceuticals made a net profit of EUR -3.60 mil in 2019, up 0% compared to the previous year. Historically, between ...
| Profit Statement | 2022 | 2023 | 2024 | |
| Sales | EUR mil | 77.4 | 85.9 | 93.8 |
| EBITDA | EUR mil | 5.06 | 9.49 | 12.3 |
| EBIT | EUR mil | 2.09 | 7.23 | 10.6 |
| Pre-Tax Profit | EUR mil | 1.51 | 6.48 | 9.73 |
| Net Profit | EUR mil | 1.51 | 5.25 | 7.59 |
| Dividends | EUR mil | 1.24 | 4.69 | 6.83 |
| Balance Sheet | 2022 | 2023 | 2024 | |
| Total Assets | EUR mil | 58.4 | 61.3 | 63.2 |
| Non-Current Assets | EUR mil | 27.9 | 26.6 | 26.6 |
| Current Assets | EUR mil | 30.5 | 34.7 | 36.6 |
| Working Capital | EUR mil | 22.7 | 24.3 | 25.7 |
| Shareholders' Equity | EUR mil | 26.5 | 30.5 | 33.4 |
| Liabilities | EUR mil | 31.9 | 30.8 | 29.8 |
| Total Debt | EUR mil | 16.7 | 15.1 | 13.6 |
| Net Debt | EUR mil | 16.7 | 13.1 | 11.6 |
| Ratios | 2022 | 2023 | 2024 | |
| ROE | % | 5.90 | 18.4 | 23.8 |
| ROCE | % | 2.96 | 10.3 | 14.7 |
| EBITDA Margin | % | 6.54 | 11.0 | 13.1 |
| EBIT Margin | % | 2.70 | 8.41 | 11.3 |
| Net Margin | % | 1.95 | 6.11 | 8.10 |
| Net Debt/EBITDA | 3.30 | 1.38 | 0.943 | |
| Net Debt/Equity | % | 62.9 | 43.1 | 34.8 |
| Valuation | 2022 | 2023 | 2024 | |
| Market Capitalisation | USD mil | 22.8 | 22.8 | 22.8 |
| Enterprise Value (EV) | USD mil | 41.5 | 37.5 | 35.8 |
| Number Of Shares | mil | 1.00 | 1.00 | 1.00 |
| Share Price | EUR | 20.3 | 20.3 | 20.3 |
| EV/EBITDA | 7.24 | 3.49 | 2.57 | |
| EV/Sales | 0.473 | 0.385 | 0.337 | |
| Price/Earnings (P/E) | 13.5 | 3.87 | 2.68 | |
| Price/Book Value (P/BV) | 0.767 | 0.666 | 0.608 | |
| Dividend Yield | % | 6.10 | 23.1 | 33.6 |
Get all company financials in excel:
| overview | Unit | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| income statement | |||||||||||||
| Sales | EUR mil | 49.2 | 35.8 | 57.5 | 62.1 | 69.6 | ... | ||||||
| EBIT | EUR mil | -1.56 | 0.202 | -3.33 | -0.209 | -0.529 | ... | ||||||
| Net Profit | EUR mil | -1.50 | 0 | -3.60 | -0.672 | 0.995 | ... | ||||||
| ROE | % | ... | -5.80 | 0 | -14.8 | -2.80 | 4.11 | ... | |||||
| EBIT Margin | % | ... | ... | ... | ... | 0.565 | -5.80 | -0.337 | -0.759 | ... | |||
| Net Margin | % | ... | ... | ... | ... | 0 | -6.26 | -1.08 | 1.43 | ... | |||
| balance sheet | |||||||||||||
| Total Assets | EUR mil | ... | ... | ... | ... | 44.8 | 51.9 | 56.3 | 59.0 | ... | |||
| Non-Current Assets | EUR mil | ... | ... | ... | ... | 14.2 | 19.6 | 29.7 | 30.1 | ... | |||
| Current Assets | EUR mil | ... | ... | ... | ... | 30.2 | 31.2 | 26.5 | 28.9 | ... | |||
| Shareholders' Equity | EUR mil | 25.8 | 24.3 | 24.3 | 23.7 | 24.7 | ... | ||||||
| Liabilities | EUR mil | ... | ... | ... | ... | 20.4 | 27.6 | 32.6 | 34.3 | ... | |||
| Non-Current Liabilities | EUR mil | ... | ... | ... | ... | 11.3 | 10.8 | 18.0 | 17.4 | ... | |||
| Current Liabilities | EUR mil | ... | ... | ... | ... | 9.06 | 16.7 | 14.6 | 16.9 | ... | |||
| Net Debt/EBITDA | ... | ... | ... | ... | -1.52 | -5.20 | 8.29 | 9.96 | ... | ||||
| Net Debt/Equity | % | ... | ... | ... | ... | -11.0 | 35.7 | 72.6 | 78.1 | ... | |||
| cash flow | |||||||||||||
| Total Cash From Operations | EUR mil | ... | ... | ... | ... | ... | -0.519 | 3.24 | 1.31 | ... | |||
| Total Cash From Investing | EUR mil | ... | ... | ... | ... | ... | -3.69 | -11.3 | -2.83 | ... | |||
| Total Cash From Financing | EUR mil | ... | ... | ... | ... | ... | 2.11 | 8.64 | 0.518 | ... | |||
| Net Change In Cash | EUR mil | ... | ... | ... | ... | ... | -2.10 | 0.605 | -0.996 | ... | |||
| valuation | |||||||||||||
| Market Capitalisation | USD mil | ... | ... | ... | ... | 23.3 | 22.8 | 22.8 | 22.8 | ... | |||
| Enterprise Value (EV) | USD mil | ... | ... | ... | ... | 20.2 | 32.5 | 42.1 | 44.4 | ... | |||
| Number Of Shares | mil | ... | ... | ... | ... | 1.00 | 1.00 | 1.00 | 1.00 | ... | |||
| Share Price | EUR | ... | ... | ... | ... | 20.3 | 20.3 | 20.3 | 20.3 | ... | |||
| Price/Earnings (P/E) | ... | ... | ... | ... | ... | -5.64 | -30.2 | 20.4 | ... | ||||
| Price/Cash Earnings (P/CE) | ... | ... | ... | ... | 13.0 | -10.5 | 12.6 | 5.87 | ... | ||||
| EV/EBITDA | ... | ... | ... | ... | 9.77 | -17.2 | 17.9 | 20.2 | ... | ||||
| Price/Book Value (P/BV) | ... | ... | ... | ... | 0.834 | 0.834 | 0.858 | 0.823 | ... | ||||
| Dividend Yield | % | ... | ... | ... | ... | 0 | 0 | 0 | 0 | ... |
| income statement | Unit | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| income statement | |||||||||||||
| Sales | EUR mil | 49.2 | 35.8 | 57.5 | 62.1 | 69.6 | ... | ||||||
| EBITDA | EUR mil | 0.100 | 1.76 | -1.67 | 2.07 | 1.94 | ... | ||||||
| Depreciation | EUR mil | 1.66 | 1.56 | 1.66 | 2.28 | 2.46 | ... | ||||||
| EBIT | EUR mil | -1.56 | 0.202 | -3.33 | -0.209 | -0.529 | ... | ||||||
| Net Financing Cost | EUR mil | ... | ... | ... | 0.003 | 0.160 | 0.160 | 0.463 | 0.577 | ... | |||
| Pre-Tax Profit | EUR mil | ... | -1.66 | 0.042 | -3.60 | -0.672 | 0.995 | ... | |||||
| Tax | EUR mil | ... | -0.164 | 0 | 0 | 0 | 0 | ... | |||||
| Net Profit | EUR mil | -1.50 | 0 | -3.60 | -0.672 | 0.995 | ... | ||||||
| Net Profit Avail. to Common | EUR mil | -1.50 | 0 | -3.60 | -0.672 | 0.995 | ... | ||||||
| Dividends | EUR mil | ... | 0 | 0 | 0 | 0 | 0 | ... | |||||
| growth rates | |||||||||||||
| Total Revenue Growth | % | ... | 1.23 | -27.2 | 60.6 | 7.94 | 12.2 | ... | |||||
| EBITDA Growth | % | ... | -95.7 | 1,663 | -195 | -224 | -6.65 | ... | |||||
| EBIT Growth | % | ... | 0 | ... | -1,747 | -93.7 | 153 | ... | |||||
| Pre-Tax Profit Growth | % | ... | ... | -3,094 | -103 | -8,651 | -81.3 | -248 | ... | ||||
| Net Profit Growth | % | ... | ... | -100 | ... | -81.3 | -248 | ... | |||||
| ratios | |||||||||||||
| ROE | % | ... | -5.80 | 0 | -14.8 | -2.80 | 4.11 | ... | |||||
| ROA | % | ... | ... | ... | ... | ... | -7.45 | -1.24 | 1.73 | ... | |||
| ROCE | % | ... | ... | ... | ... | 0 | -9.48 | -1.52 | 1.99 | ... | |||
| EBITDA Margin | % | ... | ... | ... | ... | 4.92 | -2.90 | 3.34 | 2.78 | ... | |||
| EBIT Margin | % | ... | ... | ... | ... | 0.565 | -5.80 | -0.337 | -0.759 | ... | |||
| Net Margin | % | ... | ... | ... | ... | 0 | -6.26 | -1.08 | 1.43 | ... | |||
| Payout Ratio | % | ... | ... | 0 | ... | 0 | 0 | 0 | ... | ||||
| Net Debt/EBITDA | ... | ... | ... | ... | -1.52 | -5.20 | 8.29 | 9.96 | ... |
| balance sheet | Unit | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| balance sheet | |||||||||||||
| Cash & Cash Equivalents | EUR mil | ... | ... | ... | ... | 2.69 | 0.586 | 1.19 | 0.195 | ... | |||
| Receivables | EUR mil | ... | ... | ... | ... | 8.76 | 11.9 | 9.01 | 10.1 | ... | |||
| Inventories | EUR mil | ... | ... | ... | ... | 18.8 | 18.7 | 16.3 | 18.6 | ... | |||
| Other ST Assets | EUR mil | ... | ... | ... | ... | 0 | 0 | 0 | < -0.001 | ... | |||
| Current Assets | EUR mil | ... | ... | ... | ... | 30.2 | 31.2 | 26.5 | 28.9 | ... | |||
| Property, Plant & Equipment | EUR mil | ... | ... | ... | ... | 14.0 | 19.3 | 28.3 | 28.7 | ... | |||
| LT Investments & Receivables | EUR mil | ... | ... | ... | ... | 0 | 0 | 0 | 0 | ... | |||
| Intangible Assets | EUR mil | ... | ... | ... | ... | 0.236 | 0.298 | 0.248 | 0.198 | ... | |||
| Goodwill | EUR mil | ... | ... | ... | ... | 0 | 0 | 0 | 0 | ... | |||
| Non-Current Assets | EUR mil | ... | ... | ... | ... | 14.2 | 19.6 | 29.7 | 30.1 | ... | |||
| Total Assets | EUR mil | ... | ... | ... | ... | 44.8 | 51.9 | 56.3 | 59.0 | ... | |||
| Trade Payables | EUR mil | ... | ... | ... | ... | 5.77 | 10.2 | 6.52 | 7.33 | ... | |||
| Short-Term Debt | EUR mil | ... | ... | ... | ... | 0 | 3.85 | 5.68 | 7.28 | ... | |||
| Other ST Liabilities | EUR mil | ... | ... | ... | ... | 3.29 | 2.65 | 2.38 | 2.29 | ... | |||
| Current Liabilities | EUR mil | ... | ... | ... | ... | 9.06 | 16.7 | 14.6 | 16.9 | ... | |||
| Long-Term Debt | EUR mil | ... | ... | ... | ... | 0 | 5.42 | 12.7 | 12.2 | ... | |||
| Other LT Liabilities | EUR mil | ... | ... | ... | ... | 11.3 | 5.41 | 5.32 | 5.23 | ... | |||
| Non-Current Liabilities | EUR mil | ... | ... | ... | ... | 11.3 | 10.8 | 18.0 | 17.4 | ... | |||
| Liabilities | EUR mil | ... | ... | ... | ... | 20.4 | 27.6 | 32.6 | 34.3 | ... | |||
| Equity Before Minority Interest | EUR mil | 23.7 | 23.7 | 23.7 | 23.7 | 24.7 | ... | ||||||
| Minority Interest | EUR mil | 0 | 0 | 0 | 0 | 0 | ... | ||||||
| Equity | EUR mil | 25.8 | 24.3 | 24.3 | 23.7 | 24.7 | ... | ||||||
| growth rates | |||||||||||||
| Total Asset Growth | % | ... | ... | ... | ... | ... | 16.0 | 8.38 | 4.86 | ... | |||
| Shareholders' Equity Growth | % | ... | 0 | -5.80 | 0 | -2.76 | 4.20 | ... | |||||
| Net Debt Growth | % | ... | ... | ... | ... | ... | -423 | 97.9 | 12.2 | ... | |||
| Total Debt Growth | % | ... | ... | ... | ... | ... | ... | 98.2 | 5.96 | ... | |||
| ratios | |||||||||||||
| Total Debt | EUR mil | ... | ... | ... | ... | 0 | 9.27 | 18.4 | 19.5 | ... | |||
| Net Debt | EUR mil | ... | ... | ... | ... | -2.69 | 8.68 | 17.2 | 19.3 | ... | |||
| Working Capital | EUR mil | ... | ... | ... | ... | 21.8 | 20.4 | 18.8 | 21.4 | ... | |||
| Capital Employed | EUR mil | ... | ... | ... | ... | 36.0 | 39.9 | 48.6 | 51.5 | ... | |||
| Net Debt/Equity | % | ... | ... | ... | ... | -11.0 | 35.7 | 72.6 | 78.1 | ... | |||
| Current Ratio | ... | ... | ... | ... | 3.34 | 1.86 | 1.82 | 1.71 | ... | ||||
| Quick Ratio | ... | ... | ... | ... | 1.26 | 0.744 | 0.700 | 0.609 | ... |
| cash flow | Unit | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| cash flow | |||||||||||||
| Net Profit | EUR mil | -1.50 | 0 | -3.60 | -0.672 | 0.995 | ... | ||||||
| Depreciation | EUR mil | 1.66 | 1.56 | 1.66 | 2.28 | 2.46 | ... | ||||||
| Non-Cash Items | EUR mil | ... | ... | ... | ... | ... | 0 | 0.092 | 0.407 | ... | |||
| Change in Working Capital | EUR mil | ... | ... | ... | ... | ... | 1.42 | 1.53 | -2.55 | ... | |||
| Total Cash From Operations | EUR mil | ... | ... | ... | ... | ... | -0.519 | 3.24 | 1.31 | ... | |||
| Capital Expenditures | EUR mil | ... | ... | ... | ... | ... | -3.69 | -11.3 | -2.83 | ... | |||
| Other Investing Activities | EUR mil | ... | ... | ... | ... | ... | 0 | 0 | 0 | ... | |||
| Total Cash From Investing | EUR mil | ... | ... | ... | ... | ... | -3.69 | -11.3 | -2.83 | ... | |||
| Dividends Paid | EUR mil | ... | ... | ... | ... | ... | 0 | 0 | 0 | ||||
| Issuance Of Debt | EUR mil | ... | ... | ... | ... | ... | 9.27 | 9.11 | 1.09 | ... | |||
| Total Cash From Financing | EUR mil | ... | ... | ... | ... | ... | 2.11 | 8.64 | 0.518 | ... | |||
| Effect of FX Rates | EUR mil | ... | ... | ... | ... | ... | 0 | 0 | 0 | ... | |||
| Net Change In Cash | EUR mil | ... | ... | ... | ... | ... | -2.10 | 0.605 | -0.996 | ... | |||
| ratios | |||||||||||||
| Days Sales Outstanding | days | ... | ... | ... | ... | 89.3 | 75.3 | 53.0 | 53.0 | ... | |||
| Cash Earnings | EUR mil | ... | ... | ... | ... | 1.56 | -1.94 | 1.61 | 3.46 | ... | |||
| Free Cash Flow | EUR mil | ... | ... | ... | ... | ... | -4.21 | -8.04 | -1.51 | ... | |||
| Capital Expenditures (As % of Sales) | % | ... | ... | ... | ... | ... | 6.42 | 18.2 | 4.06 | ... |
| other ratios | Unit | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Effective Tax Rate | % | ... | ... | ... | ... | 0 | 0 | 0 | 0 | ... | |||
| Total Revenue Growth (5-year average) | % | ... | ... | ... | ... | ... | -3.78 | 1.61 | 7.46 | ... | |||
| Total Revenue Growth (10-year average) | % | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... |
| valuation | Unit | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Market Capitalisation | USD mil | ... | ... | ... | ... | 23.3 | 22.8 | 22.8 | 22.8 | ... | |||
| Enterprise Value (EV) | USD mil | ... | ... | ... | ... | 20.2 | 32.5 | 42.1 | 44.4 | ... | |||
| Number Of Shares | mil | ... | ... | ... | ... | 1.00 | 1.00 | 1.00 | 1.00 | ... | |||
| Share Price | EUR | ... | ... | ... | ... | 20.3 | 20.3 | 20.3 | 20.3 | ... | |||
| EV/EBITDA | ... | ... | ... | ... | 9.77 | -17.2 | 17.9 | 20.2 | ... | ||||
| Price/Earnings (P/E) | ... | ... | ... | ... | ... | -5.64 | -30.2 | 20.4 | ... | ||||
| Price/Cash Earnings (P/CE) | ... | ... | ... | ... | 13.0 | -10.5 | 12.6 | 5.87 | ... | ||||
| P/FCF | ... | ... | ... | ... | ... | -4.82 | -2.53 | -13.4 | ... | ||||
| Price/Book Value (P/BV) | ... | ... | ... | ... | 0.834 | 0.834 | 0.858 | 0.823 | ... | ||||
| Dividend Yield | % | ... | ... | ... | ... | 0 | 0 | 0 | 0 | ... | |||
| Free Cash Flow Yield | % | ... | ... | ... | ... | ... | -20.9 | -40.0 | -7.53 | ... | |||
| Earnings Per Share (EPS) | EUR | ... | ... | ... | ... | 0 | -3.60 | -0.672 | 0.995 | ... | |||
| Cash Earnings Per Share | EUR | ... | ... | ... | ... | 1.56 | -1.94 | 1.61 | 3.46 | ... | |||
| Free Cash Flow Per Share | EUR | ... | ... | ... | ... | ... | -4.21 | -8.04 | -1.51 | ... | |||
| Book Value Per Share | EUR | ... | ... | ... | ... | 24.3 | 24.3 | 23.7 | 24.7 | ... | |||
| Dividend Per Share | EUR | ... | ... | ... | ... | 0 | 0 | 0 | 0 | ... | |||
| EV/Sales | ... | ... | ... | ... | 0.481 | 0.499 | 0.598 | 0.563 | ... | ||||
| EV/EBIT | ... | ... | ... | ... | 85.1 | -8.61 | -177 | -74.1 | ... | ||||
| EV/Free Cash Flow | ... | ... | ... | ... | ... | -6.81 | -4.62 | -25.9 | ... | ||||
| EV/Capital Employed | ... | ... | ... | ... | 0.490 | 0.726 | 0.772 | 0.769 | ... | ||||
| Earnings Per Share Growth | % | ... | ... | ... | ... | ... | ... | -81.3 | -248 | ... | |||
| Cash Earnings Per Share Growth | % | ... | ... | ... | ... | ... | -224 | -183 | 115 | ... | |||
| Book Value Per Share Growth | % | ... | ... | ... | ... | ... | 0 | -2.76 | 4.20 | ... |
Get all company financials in excel:
By Helgi Library - November 25, 2020
Saneca Pharmaceuticals made a net profit of EUR -3.60 mil in 2019, up 0% compared to the previous year. Historically, between 2014 and 2019, the company's net profit reached a high of EUR 6.60 mil in 2014 and a low of EUR -3.60 mil in 2019. The result imp...
By Helgi Library - November 24, 2020
Saneca Pharmaceuticals made a net profit of EUR -3.60 mil with revenues of EUR 57.5 mil in 2019, up by 0% and up by 60.6%, respectively, compared to the previous year. This translates into a net margin of -6.26%. Historically, between 2018 and 2019, ...
By Helgi Library - November 24, 2020
Saneca Pharmaceuticals's operating cash flow stood at EUR -0.519 mil in 2019, up 0% when compared to the previous year. Historically, between 2019 - 2019, the firm’s operating cash flow reached a high of EUR -0.519 mil in 2019 and a low of EUR -0.519 m...
By Helgi Library - November 24, 2020
Saneca Pharmaceuticals made a net profit of EUR -3.60 mil with revenues of EUR 57.5 mil in 2019, up by 0% and up by 60.6%, respectively, compared to the previous year. This translates into a net margin of -6.26%. Historically, between 2018 and 2019, ...
By Helgi Library - November 24, 2020
Saneca Pharmaceuticals's operating cash flow stood at EUR -0.519 mil in 2019, up 0% when compared to the previous year. Historically, between 2019 - 2019, the firm’s operating cash flow reached a high of EUR -0.519 mil in 2019 and a low of EUR -0.519 m...
By Helgi Library - November 24, 2020
Saneca Pharmaceuticals's net debt stood at EUR 8.68 mil and accounted for 35.7% of equity at the end of 2019. The ratio is up 46.7 pp compared to the previous year. Historically, the firm’s net debt to equity reached a high of 35.7% in 2019 and a...
By Helgi Library - November 24, 2020
Saneca Pharmaceuticals stock traded at EUR 20.3 per share at the end 2019 translating into a market capitalization of USD 22.8 mil. Since the end of 2014, the stock has appreciated by 0% representing an annual average growth of %. At the end of 2019, the...
By Helgi Library - November 24, 2020
Saneca Pharmaceuticals invested a total of EUR 3.69 mil in 2019, down 0% compared to the previous year. Historically, between 2019 - 2019, the company's investments stood at a high of EUR 3.69 mil in 2019 and a low of EUR 3.69 mil in 2019. ...
By Helgi Library - November 24, 2020
Saneca Pharmaceuticals stock traded at EUR 20.3 per share at the end 2019 implying a market capitalization of USD 22.8 mil. Since the end of 2014, stock has appreciated by % implying an annual average growth of % In absolute terms, the value of the company ...
By Helgi Library - November 24, 2020
Saneca Pharmaceuticals's net debt stood at EUR 8.68 mil and accounted for 35.7% of equity at the end of 2019. The ratio is up 46.7 pp compared to the previous year. Historically, the firm’s net debt to equity reached a high of 35.7% in 2019 and a...
Saneca Pharmaceuticals is a Slovakia-based pharmaceutical Company that develops and produces pharmaceutical dosage forms, including solid, liquids, gels and creams. The Company (previously known as Slovakofarma) has been merged with Léčiva in 2003 to create Zentiva, taken over in 2009 by Sanofi and a de-merged and acquired by Wood Pharma Holding in 2013. Saneca still generated almost half of total production for Sanofi in 2020. However, increasing part of Company's production should be directed towards active pharmaceutical ingredients (API) and sold to third parties. The share should increase from 24% of total sales in 2020 to almost 33% in 2024, according the management plans.
Saneca Pharmaceuticals has been growing its sales by a year on average in the last 5 years. EBITDA has grown by 0% during that time to total of in 2025, or of sales. That’s compared to 8.38% average margin seen in last five years.
The company netted in 2025 implying ROE of and ROCE of . Again, the average figures were 13.1% and 7.50%, respectively when looking at the previous 5 years.
Saneca Pharmaceuticals’s net debt amounted to at the end of 2025, or of equity. When compared to EBITDA, net debt was x, down when compared to average of 3.90x seen in the last 5 years.
Saneca Pharmaceuticals stock traded at per share at the end of 2025 resulting in a market capitalization of . Over the previous five years, stock price grew by 0% or % a year on average. The closing price put stock at a 12-month trailing EV/EBITDA of x and price to earnings (PE) of x as of 2025.
Helgi Library 
